Assessment of oral antithrombotic therapy by platelet function testing

Nature Reviews Cardiology

Volumn 8, Issue 10, 2011, Pages 572-579

  Tantry, Udaya S ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN; ELINOGREL; PLACEBO; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANALYZER; ANTICOAGULANT THERAPY; BLEEDING; BLEEDING TIME; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION RISK; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG MONITORING; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 80053268406     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.107     Document Type: Review

References (62)

1. Tantry, U. S, Etherington, A., Bliden, K. P & Gurbel, P. A. Antiplatelet therapy: current strategies and future trends. Future Cardiol. 2, 343-366 (2006).
2. Kolh, P. et al. Guidelines on myocardial revascularization. Eur. J. Cardiothorac. Surg. 38, S1-S52 (2010).
3. Gurbel, P. A., Bliden, K. P., Hiatt, B. L. & O'Conner, C. M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003). (Pubitemid 36736631)
4. Bonello, L. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010).
5. Wright, R. S. et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction (updating the 2007 guideline) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 57, 1920-1959 (2011 ).
6. Society of Thoracic Surgeons Blood Conservation Guideline Task Force et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann. Thorac. Surg. 91, 944-982 (2011).
7. Lip, G. Y. et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary-a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 31, 1311-1318 (2010).
8. Holmes D. R. Jr et al. Combining antiplatelet and anticoagulant therapies. J. Am. Coll. Cardiol. 54, 95-109 (2009).
9. Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007). (Pubitemid 351650486)
10. Rubboli, A., Milandri, M., Castelvetri, C. & Cosmi, B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 104, 101-106 (2005). (Pubitemid 41197020)
11. Karjalainen, P. P. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur. Heart J. 28, 726-732 (2007). (Pubitemid 46439228)
12. ACTIVE Writing Group of the ACTIVE Investigators et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
13. Hansen, M. L. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170, 1433-1441 (2010).
14. ACTIVE Investigators et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066-2078 (2009).
15. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
16. Zhao, H. J. et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 139, 260-270 (2011).
17. Gurbel, P. A. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46, 1820-1826 (2005). (Pubitemid 41579802)
18. Gurbel, P. A. et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 19, 595-604 (2008).
19. Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R. & Michelson, A. D. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1822-1834 (2007). (Pubitemid 350007957)
20. Sibbing, D., Steinhubl, S. R., Schulz, S., Schömig, A. & Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J. Am. Coll. Cardiol. 56, 317-318 (2010).
21. Becker, R. C. & Gurbel, P. A. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb. Haemost. 103, 535-44 (2010).
22. Gurbel, P. A. & Tantry, U. S. Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. Curr. Treat. Options Cardiovasc. Med. 11, 22-32 (2009).
23. Rao, S. V. et al. Bleeding and blood transfusion issues in patients with non ST segment elevation acute coronary syndromes. Eur. Heart J. 28, 1193-1204 (2007). (Pubitemid 47343833)
24. Vavalle, J. P. & Rao, S. V. Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interv. Cardiol. 1, 51-62 (2009).
25. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med. 345, 494-502 (2001). (Pubitemid 32758501)
26. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
27. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
28. Paikin, J. S., Wright, D. S. & Eikelboom, J. W. Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev. 25, 123-129 (2011).
29. Steffel, J. & Braunwald, E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur. Heart J. doi: 101093/eurheartj/ehr052
30. van Ryn, J. et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
31. Barrett, Y. C., Wang, Z., Frost, C. & Shenker, A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost. 104, 1263-1267 (2010).
32. Seegmiller, A. & Sarode, R. Laboratory evaluation of platelet function. Hematol. Oncol. Clin. North Am. 21, 731-742 (2007). (Pubitemid 47102563)
33. Peddinghaus, M. E. & Tormey, C. A. Platelet-related bleeding: an update on diagnostic modalities and therapeutic options. Clin. Lab. Med. 29, 175-191 (2009).
34. Breet, N. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
35. Born, G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194, 927-929 (1962).
36. Gurbel, P. A. et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am. Heart J. 160, 346-354 (2010).
37. Price, M. J. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-1105 (2011).
38. Chen, L. et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 128, 425-431 (2004). (Pubitemid 39194700)
39. Cuisset, T. et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5, 325-329 (2009).
40. Serebruany, V. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur. Heart J. 31, 227-235 (2010).
41. Wegner, J. & Popovsky, M. A. Clinical utility of thromboelastography: one size does not fit all. Semin. Thromb. Hemost. 36, 699-706 (2010).
42. Spiess, B. D. Thromboelastography and cardiopulmonary bypass. Semin. Thromb. Hemost. 21, 27-33 (1995). (Pubitemid 26015178)
43. Nuttall, G. A. et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 94, 773-781 (2001). (Pubitemid 32429746)
44. Shore-Lesserson, L. et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth. Analg. 88, 312-319 (1999). (Pubitemid 29070189)
45. Mahla, E. et al. Time based strategy to reduce clopidogrel associated bleeding during CABG. Results from the TARGET CABG study. Presented at Clinical Science: Special reports, American College of Cardiology Meeting 2010
46. Kwak, Y. L. et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J. Am. Coll. Cardiol. 56, 1994-2002 (2010).
47. Wasowicz, M. et al. The incremental value of thrombelastography for prediction of excessive blood loss after cardiac surgery: an observational study. Anesth. Analg. 111, 331-338 (2010).
48. Kratzer, M. A. & Born, G. V. Simulation of primary haemostasis in vitro. Haemostasis 15, 357-362 (1985). (Pubitemid 16206083)
49. Favaloro, E. J. Clinical utility of the PFA 100 Semin. Thromb. Hemost. 34, 709-733 (2008).
50. Koessler, J. et al. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets 22, 19-25 (2011).
51. Linnemann, B., Schwonberg, J., Rechner, A. R., Mani, H. & Lindhoff-Last, E. Assessment of clopidogrel non-response by the PFA 100 system using the new test cartridge INNOVANCE PFA P2Y. Ann. Hematol. 89, 597-605 (2010).
52. Gurbel, P. A. et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect(ASPECT) study. Circulation 115, 3156-3164 (2007). (Pubitemid 47012230)
53. Reny, J. L., De Moerloose, P., Dauzat, M. & Fontana, P. Use of the PFA 100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J. Thromb. Haemost. 6, 444-450 (2008). (Pubitemid 351280111)
54. Mueller, T., Dieplinger, B., Poelz, W., Calatzis, A. & Haltmayer, M. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res. 121, 249-258 (2007). (Pubitemid 350148206)
55. Sibbing, D. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Hemost. 99, 121-126 (2008).
56. Sibbing, D. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8, 250-256 (2010).
57. Sibbing D. et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur. Heart. J. 31, 1205-1211 (2010).
58. Reece, M. J. et al. Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study. Anaesthesia 66, 97-103 (2011).
59. Mengistu, A. M. et al. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J. Cardiothorac. Vasc. Anesth. 22, 40-46 (2008). (Pubitemid 351179383)
60. Rahe-Meyer, N. et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol. Scand. 53, 168-175 (2009).
61. Price, M. J. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992-1000 (2008). (Pubitemid 351844676)
62. Campo, G. et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 21, 2474-2483 (2011).